Summit Therapeutics stock price target lowered to $42 by Jefferies
NegativeFinancial Markets

Jefferies has lowered the stock price target for Summit Therapeutics to $42, indicating a more cautious outlook for the company. This adjustment reflects concerns about the company's future performance and could impact investor confidence. It's important for stakeholders to stay informed as such changes can influence market dynamics and investment strategies.
— Curated by the World Pulse Now AI Editorial System